C-reactive protein as a cardiovascular risk factor more than an epiphenomenon?

Circulation

Volumn 100, Issue 1, 1999, Pages 96-102

  Lagrand, Wim K ^a   Visser, Cees A ^a   Hermens, Willem T ^b   Niessen, Hans W M ^a   Verheugt, Freek W A ^c   Wolbink, Gert Jan ^d   Hack, C Erik ^a,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CENTRAL LABORATORY   (Netherlands)

Author keywords

Cardiovascular diseases; Inflammation; Myocardial infarction; Physiology; Risk factors

Indexed keywords

C REACTIVE PROTEIN;

CARDIOVASCULAR DISEASE; COMPLEMENT SYSTEM; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS;

EID: 0033529379     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.1.96     Document Type: Review

References (70)

1. Ross T. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. Libby P. Molecular basis of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
3. Ridker PM. C-reactive protein and risks of future myocardial infarction and thrombotic stroke. Eur Heart J. 1998;19:1-3.
4. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
5. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312:1061-1065.
6. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 1996;144:537-547.
7. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
8. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Arterioscler Thromb Vasc Biol. 1997;17:1121-1127.
9. de Beer FC, Hind CRK, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J. 1982;47:239-243.
10. Pietilä K, Harmoinen A, Pöyhönen L. Koskinen M, Heikkila J, Ruosteenoja R. Intravenous streptokinase treatment and serum C-reactive protein in patients with acute myocardial infarction. Br Heart J. 1987;58:225-229.
11. Pietilä K, Harmoinen A, Teppo A-M. Acute phase reaction, infarct size and in-hospital morbidity in myocardial infarction patients treated with streptokinase or recombinant tissue type plasminogen activator. Ann Med. 1991;23:529-535.
12. Pietilä KO, Harmoinen AP, Hermens WT, Simoons ML, van de Werf F, Verstraete M. Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. Eur Heart J. 1993;14:915-919.
13. Casl MT, Surina B, Glojnaric-Spasic I, Pape E, Jagarinec N, Kranjcevic S. Serum amyloid A protein in patients with acute myocardial infarction. Ann Clin Biochem. 1995;32:196-200.
14. Pietilä KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J. 1996;17:1345-1349.
15. Ueda S, Ikeda U, Yamamoto K, Takahashi M, Nishinaga M, Nago N, Shimada K. C-reactive protein as a predictor of cardiac rupture after myocardial infarction. Am Heart J. 1996;131:857-860.
16. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, Ogawa S. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q wave acute myocardial infarction. Circulation. 1997;96:778-784.
17. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 1990;65:168-172.
18. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331: 417-424.
19. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462-466.
20. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation. 1997;96:4204-4210.
21. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet. 1996;348:567-572.
22. Patel P, Mendall MA, Carrington D, Strachan D, Leatham E, Molineaux N. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ. 1995;311:711-714.
23. Melnick JL, Adam E, DeBakey ME. Possible role of cytomegalovirus in atherogenesis. JAMA. 1990;263:2204-2207.
24. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-436.
25. Gitlin JD, Gitlin JI, Gitlin D. Localization of C-reactive protein in synovium of patients with rheumatoid arthritis. Arthritis Rheum. 1977; 20:1491-1499.
26. Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method. Pathol Int. 1995;45:635-641.
27. Kushner I, Rakita I, Kaplan MH. Studies of acute-phase protein, II: localization of Cx-protein in heart in induced myocardial infarction in rabbits. J Clin Invest. 1963;42:286-292.
28. Lagrand WK, Niessen JWM, Wolbink GJ, Jaspars EH, Visser CA, Verheugt FWA, Meijer CJLM, Hack CE. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation. 1997;95:97-103.
29. Castell JV, Andus T, Kunz D, Heinrich PC. Interleukin-6: the major regulator of acute-phase protein synthesis in man and rat. Ann N Y Acad Sci. 1989;557:87-101.
30. Neumann F-J, Ott I, Gawaz M, Richardt G, Holzapfel H, Jochum M, Schömig A. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 1995;92:748-755.
31. Gauldie J, Richards C, Northemann W, Fey G, Baumann H. IFNb2/ BSF2/IL-6 is the monocyte-derived HSF that regulates receptor specific acute phase gene regulation in hepatocytes. Ann N Y Acad Sci. 1989;557: 46-59.
32. Agrawal A, Kilpatrick JM, Volanakis JE. Structure and function of human C-reactive protein. In: Mackiewicz A, Kushner I, Baumann H, eds. Acute Phase Proteins. Molecular Biology, Biochemistry, and Clinical Applications. Boca Raton, Fla: CRC Press, Inc; 1993:79-92.
33. Heuertz RM, Piquette CA, Webster RO. Rabbits with elevated serum C-reactive protein exhibit diminished neutrophil infiltration and vascular permeability in C5a-induced alveolitis. Am J Pathol. 1993;142:319-328.
34. Volanakis JE. Complement activation by C-reactive protein complexes. Ann N Y Acad Sci. 1982;389:235-249.
35. Biasucci LM, de Maat MPM, Meo A, van der Greef W, Summaria F, Quaranta G, Liuzzo G, Kluft C, Maseri A. Analysis of activation markers of coagulation, fibrinolysis and inflammation in unstable angina by probit transformation. Fibrinolysis. 1996;10(suppl 2):145-147.
36. Heinrich J, Schulte H, Schönfeld R, Köhler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost. 1995;73:374-378.
37. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentrations of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425-428.
38. de Maat MPM, de Bart ACW, Hennis BC, Meijer HP, Havelaar AC, Mulder PGH, Kluft C. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol. 1996;16:1156-1162.
39. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997;43:52-58.
40. Biasucci LM, Liuzzo G, Caligiura G, van de Greef W, Quaranta G, Monaco C, Rebuzzi AG, Kluft C, Maseri A. Episodic activation of the coagulation system in unstable angina does not elicit an acute phase response. Am J Cardiol. 1996;77:85-87.
41. Liuzzo G, Biasucci LM, Rebuzzi AG, Gallimore R, Caligiuri G, Lanza GA, Quaranta G, Monaco C, Pepys MB, Maseri A. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation. 1996;94:2373-2380.
42. GISSI. Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet. 1987;2: 871-874.
43. Hansson GK. Immune and inflammatory mechanisms in the development of atherosclerosis. Br Heart J. 1993;69(suppl):S38-S41.
44. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996;94:874-877.
45. Tilg H, Mair J, Herold M, Aulitzky WE, Lechleitner P, Dienstl F, Huber C. Acute phase response after myocardial infarction: correlation between serum levels of cytokines and C-reactive protein. Klin Wochenschr. 1990;68:1083.
46. Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJM, Hack CE. CRP-mediated activation of complement in vivo. Assessment by measuring circulating complement-C-reactive protein complexes. J Immunol. 1996;157:473-479.
47. Seifen PS, Kazatchkine MD. The complement system in atherosclerosis. Atherosclerosis. 1988;73:91-104.
48. Kilgore KS, Friedrichs GS, Homeister JW, Lucchesi BR. The complement system in myocardial ischemia/reperfusion injury. Cardiovasc Res. 1994;28:437-444.
49. Pinckard RN, Olson MS, Giclas PC, Terry R, Boyer JT, O'Rourke RA. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest. 1975;56:740-750.
50. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation. 1995;91:393-402.
51. Maroko PR, Carpenter CB, Chiariello M, Fishbein MC, Radvany P, Kostman JD, Hale SL. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest. 1978;61:661-670.
52. Weisman HF, Bartow T, Leppo MK, Marsh HC, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990;249: 146-151.
53. Hugo F, Hamdoch T, Mathey D, Schäfer H, Bhakdi S. Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin Exp Immunol. 1990;81:132-136.
54. Mathey D, Schofer J, Schäfer HJ, Hamdoch T, Joachim HC, Ritgen A, Hugo F, Bhakdi S. Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion. Eur Heart J. 1994;15:418-423.
55. Engler RL, Schmid-Schonbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol. 1983;111:98-111.
56. Carson SD, Johnson DR. Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. Blood. 1990;762:361-367.
57. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for the assembly of the prothrombinase enzyme complex. J Biol Chem. 1990;265:3809-3814.
58. DelBalzo UH, Levi R, Polly MJ. Cardiac dysfunction caused by purified human C3a anaphylatoxins. Proc Natl Acad Sci USA. 1985;82:886-890.
59. Homeister JW, Satoh P, Lucchesi BR. Effects of complement activation in the isolated heart. Circ Res. 1992;71:303-319.
60. Rowe IF, Soutar AK, Trayner IM, Thompson GR, Pepys MB. Circulating human C-reactive protein binds very low density lipoproteins. Clin Exp Immunol. 1984;58:237-244.
61. Volanakis JE, Narkates AJ. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. J Immunol. 1981; 126:1820-1825.
62. Mori S, Nakata Y, Endo H. Involvements of fibronectin and lysophosphatidylcholine for selective binding of C-reactive protein. Cell Mol Biol. 1991;37:421-431.
63. Van der Vusse GJ, van Bilsen M, Reneman RS. Ischemia and reperfusion induced alterations in membrane phospholipids: an overview. Ann N Y Acad Sci. 1994;723:1-14.
64. 2 enzymes: regulation and inhibition. Trends Pharmacol Sci. 1993;14:92-98.
65. 2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem. 1991;266:2647-2651.
66. 2 activity in clinical acute myocardial infarction. Clin Exp Pharmacol Physiol. 1992;19:113-118.
67. Zachowski A. Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement. Biochem J. 1993;294:1-14.
68. Higgins CF. Flip-flop: the transmembrane translocation of lipids. Cell. 1994;79:393-395.
69. Fourcade O, Simon M-F, Viodé C, Rugani N, Leballe F, Ragab A, Fournié B, Sarda L, Chap H. Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell. 1995;80:919-927.
70. 2 and C-reactive protein in the removal of injured cells. Immunol Today. 1997;18:111-115.